Members
Events
Join Volkan Besirlioglu, Field Application Scientist at Samplix, for a seminar on Xdrop, a breakthrough platform for single-cell functional analysis at Biomedicum Flow Cytometry Core Facility at Karolinska Institute.
Inför valet 2026 står tillgången till särläkemedel i fokus. I Almedalen möts patienter, experter, näringsliv och politiker för att diskutera reformer, ansvar och vägen framåt för svensk life science och vård.
The CGT Investor Forum, hosted by CCRM Nordic and NLSD, brings investors and ATMP innovators together on September 7, 2026, in Stockholm to explore breakthrough science, scalable therapies and the future of commercial cell and gene therapy.
The premiere nordic meetup for industry, academia and healthcare is coming to Stockholm, December 2026.
News
The European Society of Gene and Cell Therapy is looking for its next ECR Board Member. Are you a PhD student or post-doc in gene and cell therapy? Applications close 15 May 2026.
Doctoral Course: From Research to ATMP Treatment
EIB backs Swedish biotech scale-up BioLamina with €20 million to enable stem cell technologies targeting diseases such as type 1 diabetes, Parkinson’s disease, and heart failure
Karolinska Institutet offers a two-week doctoral course designed to provide a comprehensive overview of the entire process involved in developing and producing cell and gene therapy products.
Sweden is strengthening its position in advanced bioanalytics with the launch of the BioAnalytical Cluster of Excellence (BACE), supported by Vinnova.
Want to strengthen your expertise in hospital-based ATMP and cell therapy manufacturing? This three-day course in April 2026 offers practical insight into regulation, quality systems and clinical application.
Learn more about the Health Technology Assessment related issues of your ATMP development.
Support in navigating ATMP development needs prompting the right competence, need, and time.
Find or advertise ATMP relevant job opportunities.
The ATMP Sweden newsletter provides updates on Swedish ATMP- and association developments.